Skip to main content
SpringerLink
Log in

Fulfilling an Unmet Need in Psoriasis

Do Biologicals Hold the Key to Improved Tolerability?

  • Review Article
  • Published:
Drug Safety Aims and scope Submit manuscript

Abstract

Psoriasis is a chronic inflammatory disease of the skin affecting approximately 2% of the world’s population. Traditional systemic treatments, including methotrexate, ciclosporin, psoralen plus UVA (PUVA), oral retinoids and fumaric acid esters, are widely used for severe disease and are effective in the short term. Severe psoriasis is a chronic disease and patients and physicians have expressed concerns about possible harm from organ toxicity, such as skin cancer (PUVA), hyperlipidaemia (retinoids), renal (ciclosporin) or hepatotoxicity (methotrexate). Long-term monitoring is required and may not detect early organ damage. The pathophysiology of psoriasis remains to be clarified, but advances toward the understanding of the immunological basis of psoriasis have uncovered the involvement of immunological pathways; for example, the role of tumour necrosis factor (TNF)-α, T cell proliferation and T cell activation, and migration to the epidermis. This advancement in knowledge combined with developments in recombinant technologies has led to the development of target-specific therapies. Biological agents are defined as proteins that can be extracted from animal tissue or produced via recombinant DNA technologies and possess pharmacological activity. Adalimumab, alefacept, infliximab, efalizumab and etanercept are examples of biological agents currently used for the treatment of psoriasis. Some of these are also therapy for other autoimmune conditions, such as rheumatoid arthritis and Crohn’s disease. These biological agents are effective in psoriasis but raise new safety concerns. Information on the safety of biological agents in conditions such as rheumatoid arthritis and Crohn’s disease can not be directly extrapolated to psoriasis. An increased incidence of lymphomas has been postulated to be associated with etanercept, infliximab and adalimumab; serious infections, such as tuberculosis, have also been reported with these three biologicals, all of which target TNF-α. Demyelinating disorders, such as multiple sclerosis, have been reported with some biologicals as has congestive heart failure. Alefacept, because of its mechanism of action of lowering the number of active T cells, is associated with low T cell counts. Efalizumab has been associated with thrombocytopenia and haemolytic anaemia. Data on the safety of >2.5 years’ continuous treatment with efalizumab are reassuring and a valuable beginning to understanding the role and risk of harm of long-term therapy for a chronic disease. Longer follow-up studies and safety databases, for each of the biologicals used in psoriasis, are needed to ensure both prolonged efficacy and minimal risk of harm.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Table II
Table III
Fig. 1
Fig. 2
Table IV
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. van de Kerkhof PCM. Textbook of psoriasis. Oxford: Blackwell Science Ltd, 1999

    Google Scholar 

  2. Fortune DG, Main CJ, O’Sullivan TM, et al. Quality of life in patients with psoriasis: the contribution of clinical variables and psoriasis-specific stress. Br J Dermatol 1997 Nov; 137(5): 755–60

    Article  PubMed  CAS  Google Scholar 

  3. Choi J, Koo JY. Quality of life issues in psoriasis. J Am Acad Dermatol 2003 Aug; 49(2 Suppl.): S57–61

    Article  PubMed  Google Scholar 

  4. Gupta MA, Gupta AK. Psychiatric and psychological co-morbidity in patients with dermatologic disorders: epidemiology and management. Am J Clin Dermatol 2003; 4(12): 833–42

    Article  PubMed  Google Scholar 

  5. Griffiths CEM, Clark CM, Chalmers RJG, et al. A systematic review of treatment for severe psoriasis. Health Technol Assess 2000; 4(40): 1–125

    PubMed  CAS  Google Scholar 

  6. Chagan L. Alefacept: a new therapy for psoriasis. P&T 2003; 28(6): 372–83

    Google Scholar 

  7. Miiller W, Herrmann B. Cyclosporin A for psoriasis [letter]. N Engl J Med 1979; 301: 555

    Article  Google Scholar 

  8. Nickoloff BJ. The immunologic and genetic basis of psoriasis. Arch Dermatol 1999; 135: 1104–10

    Article  PubMed  CAS  Google Scholar 

  9. Singri P, West DP, Gordon KB. Biologic therapy for psoriasis: the new therapeutic frontier. Arch Dermatol 2002; 138: 657–63

    Article  PubMed  CAS  Google Scholar 

  10. Prinz JC. The role of T cells in psoriasis. J Eur Acad Dermatol Venereol 2003 May; 17(3): 257–70

    Article  PubMed  CAS  Google Scholar 

  11. Mendonca CO, Burden AD. Current concepts in psoriasis and its treatment. Pharmacol Ther 2003; 99(2): 133–47

    Article  PubMed  CAS  Google Scholar 

  12. Ryan TJ, Vickers HR, Salem SN, et al. The treatment of psoriasis with folic acid antagonists. Br J Dermatol 1964; 76: 555–64

    Article  PubMed  CAS  Google Scholar 

  13. Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus cyclosporin in moderate-to-severe chronic plaque psoriasis. N Engl J Med 2003 Aug; 349(7): 658–65

    Article  PubMed  CAS  Google Scholar 

  14. Greaves MW, Weinstein GD. Treatment of psoriasis. N Engl J Med 1995; 332(9): 581–8

    Article  PubMed  CAS  Google Scholar 

  15. Roenigk H, Auerbach R, Maibach H, et al. Methotrexate in psoriasis: revised guidelines. J Am Acad Dermatol 1998; 19: 145–56

    Article  Google Scholar 

  16. Faerber L, Braeutigam M, Weidinger G, et al. Cyclosporin in severe psoriasis: results of a meta-analysis in 579 patients. Am J Clin Dermatol 2001; 2 (1): 41–7

    Article  Google Scholar 

  17. McClure SL, Valentine J, Gordon KB. Comparative tolerability of systemic treatments for plaque-type psoriasis. Drug Saf 2002; 25(13): 913–27

    Article  PubMed  CAS  Google Scholar 

  18. Pariser D. Management of moderate to severe plaque psoriasis with biologic therapy. Manag Care 2003; 12(4): 36–44

    PubMed  Google Scholar 

  19. Garcia-Bustinduy M, Escoda M, Guimera FJ, et al. Safety of long-term treatment with cyclosporin A in resistant chronic plaque psoriasis: a retrospective case series. J Eur Acad Dermatol Venereol 2004; 18(2): 169–72

    Article  PubMed  CAS  Google Scholar 

  20. Brecher AR, Orlow SJ. Oral retinoid therapy for dermatologic conditions in children and adolescents. J Am Acad Dermatol 2003; 49(2): 171–82

    Article  PubMed  Google Scholar 

  21. Krutmann J. Therapeutic photoimmunology: photoimmunological mechanisms in photo(chemo)therapy. J Photochem Photobiol B 1998 Jul; 44(2): 159–64

    Article  PubMed  CAS  Google Scholar 

  22. Stern RS, Lunder EJ. Risk of squamous cell carcinoma and methoxsalen (psoralen) and UV-A radiation (PUVA). Arch Dermatol 1998; 134: 1582–5

    Article  PubMed  CAS  Google Scholar 

  23. Nijsten TE, Stern RS. The increased risk of skin cancer is persistent after discontinuation of psoralen+ultraviolet A: a cohort study. J Invest Dermatol 2003; 121(2): 252–8

    Article  PubMed  CAS  Google Scholar 

  24. Lindelhof B. Risk of melanoma with psoralen/ultraviolet A therapy for psoriasis: do the known risks now outweigh the benefits? Drug Saf 1999; 20(4): 289–97

    Article  Google Scholar 

  25. Stern RS, Beer JZ, Mills DK. Lack of consensus among experts on the choice of UV therapy for psoriasis. Arch Dermatol 1999; 135(10): 1187–92

    Article  PubMed  CAS  Google Scholar 

  26. Carboni I, De Felice C, De Simoni I, et al. Fumaric acid esters in the treatment of psoriasis: an Italian experience. J Dermatolog Treat 2004; 15(1): 23–6

    Article  PubMed  CAS  Google Scholar 

  27. Hoefnagel JJ, Thio HB, Willemze R, et al. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003; 149: 363–9

    Article  PubMed  CAS  Google Scholar 

  28. Raschka C, Koch HJ. Longterm treatment of psoriasis using fumaric acid preparations can be associated with severe proximal tubular damage. Hum Exp Toxicol 1999 Dec; 18(12): 738–9

    Article  PubMed  CAS  Google Scholar 

  29. Gollnick H, Altmeyer P, Kaufmann R, et al. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 2002; 205(1): 46–53

    Article  PubMed  CAS  Google Scholar 

  30. Ortonne JP. Redefining clinical response in psoriasis: targeting the pathological basis of disease. J Drugs Dermatol 2004 Jan-Feb; 3(1): 13–20

    PubMed  Google Scholar 

  31. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46(1): 1–23

    Article  PubMed  Google Scholar 

  32. Walsh SRA, Shear NH. Psoriasis and the new biologic agents: interrupting a T-AP dance. CMAJ 2004; 170(13): 1933–40

    Article  PubMed  Google Scholar 

  33. Asadullah K, Volk HD, Sterry W. Novel immunotherapies for psoriasis. Trends Immunol 2002; 23(1): 47–53

    Article  PubMed  CAS  Google Scholar 

  34. Weinberg JM. An overview of infliximab, etanercept, efalizumab and alfefacept as biologic therapy for psoriasis. Clin Ther 2003; 25(10): 2487–505

    Article  PubMed  CAS  Google Scholar 

  35. Gottlieb AB. Infliximab for psoriasis. J Am Acad Dermatol 2003 Aug; 49(2 Suppl.): S112–7

    Article  PubMed  Google Scholar 

  36. Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357(9271): 1842–7

    Article  PubMed  CAS  Google Scholar 

  37. Hanauer SB. Review article: safety of infliximab in clinical trials. Aliment Pharmacol Ther 1999; 13Suppl. 4: 16–22

    Article  PubMed  CAS  Google Scholar 

  38. Lebwohl M. New developments in the treatment of psoriasis. Arch Dermatol 2002; 138: 686–8

    Article  PubMed  Google Scholar 

  39. British National Formulary [online]. Available from URL: http://www.bnf.org.uk/bnf/bnf/50/noframes/128236.htm [Accessed 2005 Nov 30]

  40. Mease PJ, Goffe BS, Metz J, et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000; 356: 385–91

    Article  PubMed  CAS  Google Scholar 

  41. Enbrel® (etancercept) [package insert]. Thousand Oaks (CA): Immunex Corporation, 2004

  42. Enbrel® summary of product characteristics. EC Approved Annexes (II/40 psoriasis). Thousand Oaks (CA), Immunex Corporation, 2004

  43. Goffe B, Gottlieb AB, Lebwohl M, et al. Etanercept therapy results in a sustained improvement in skin and joint disease in patients with psoriatic arthritis. Poster presented at the 34th annual meeting of the European Society for Dermatological Research; Vienna 2004 Sep 3

  44. Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003; 49: S105–11

    Article  PubMed  Google Scholar 

  45. Bejaranao V, Emery P, Conaghan P. Adalimumab (Humira): biologic therapy for rheumatoid arthritis. Prescribe 2004; 15(7): 48–58

    Google Scholar 

  46. Chen DM, Gordon K, Leonardi C, et al. Adalimumab efficacy and safety in patients with moderate to severe chronic plaque psoriasis: preliminary findings from a 12-week dose-ranging trial. Abstract 2 presented at the 62nd meeting of the American Academy of Dermatology; 2004 Feb 6-11; Washington (DC)

  47. Abbott Pharmaceutical Products Division, 5 November 2004 [online]. Available from URL: http://www.fda.gov/medwatch/SAFETY/2004/HUMIRA_dhcp.pdf [Accessed 2005 Nov 30]

  48. Furst DE, Schiff MH, Fleischmann RM, et al. Adalimumab, a fully human anti tumor necrosis factor-alpha monoclonal antibody, and concomitant standard antirheumatic therapy for the treatment of rheumatoid arthritis: results of STAR (Safety Trial of Adalimumab in Rheumatoid Arthritis). J Rheumatol 2003; 30(12): 2563–71

    PubMed  CAS  Google Scholar 

  49. van de Putte LB, Atkins C, Malaise M, et al. Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed. Ann Rheum Dis 2004 May; 63(5): 508–16

    Article  PubMed  Google Scholar 

  50. Fleischmann R, Yocum D. Does safety make a difference in selecting the right TNF antagonist? Arthritis Res Ther 2004; 6(2): S12–8

    Article  PubMed  Google Scholar 

  51. Humira® [package insert]. Abbott Park (IL): Abbott Laboratories, 2002

  52. Ellis CN, Krueger GG, Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001; 345(4): 248–55

    Article  PubMed  CAS  Google Scholar 

  53. Lebwohl M, Christophers E, Alefacept Clinical Study Group. An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. Arch Dermatol 2003; 139(6): 719–27

    Article  PubMed  CAS  Google Scholar 

  54. Amevive® (alefacept) [package insert]. Cambridge (MA): Biogen Inc, 2003 Feb

  55. Gordon KB, Vaishnaw AK, Alefacept Clinical Study Group. Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. Arch Dermatol 2003; 139(12): 1563–70

    Article  PubMed  CAS  Google Scholar 

  56. Biogen Idec. AMEVIVE® (alefacept) prescribing information [online]. Available from URL: http://www.fda.gov/medwatch/safety/2005/Amevive_final_letter.pdf [Accessed 2005 Nov 30]

  57. Krueger G, Callis KP. Development and use of alefacept to treat psoriasis. J Am Acad Dermatol 2003; 49(2): S87–97

    Article  PubMed  Google Scholar 

  58. Gottlieb A. Immunobiologic agents for the treatment of psoriasis. Arch Deramtol 2003; 139: 791–3

    Article  Google Scholar 

  59. Werther WA, Gonzalez TN, O’Connor SJ, et al. Humanization of an anti-lymphocyte function-associated antigen (LFA)-1 monoclonal antibody and reengineering of the humanized antibody for binding to rhesus LFA-1. J Immunol 1996; 157(11): 4986–95

    PubMed  CAS  Google Scholar 

  60. Krueger GG, Papp KA, Alefacept Clinical Study Group. A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002 Dec; 47(6): 821–33

    Article  PubMed  Google Scholar 

  61. Jullien D, Prinz JC, Langley RG, et al. T-cell modulation for the treatment of chronic plaque psoriasis with efalizumab (Raptiva): mechanisms of action. Dermatology 2004; 208(4): 297–306

    Article  PubMed  CAS  Google Scholar 

  62. Gottlieb A, Krueger JG, Bright R, et al. Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis. J Am Acad Dermatol 2000; 42(3): 428–35

    Article  PubMed  CAS  Google Scholar 

  63. Gottlieb AB, Krueger JG, Wittkowski K, et al. Psoriasis as a model for T-cell-mediated disease: immunologic and clinical effects of treatment with multiple doses of efalizumab, an anti-CD11a antibody. Arch Dermatol 2002; 138: 591–600

    Article  PubMed  CAS  Google Scholar 

  64. Papp K, Bissonnette R, Krueger JG, et al. The treatment of moderate to severe psoriasis with a new anti-CD 11a monoclonal antibody. J Am Acad Dermatol 2001; 45(5): 665–74

    Article  PubMed  CAS  Google Scholar 

  65. Gordon KB, Papp KA, Efalizumab Study Group. Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial. JAMA 2003; 290(23): 3073–80

    Article  PubMed  CAS  Google Scholar 

  66. Lebwohl M, Tyring SK, Efalizumab Study Group. A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003; 349(21): 2004–13

    Article  PubMed  CAS  Google Scholar 

  67. Sterry W, Dubertret L, Papp K, et al. Efalizumab for patients with moderate to severe chronic plaque psoriasis: results of the international randomised, controlled phase III clinical experience acquired with raptiva (CLEAR) trial [abstract]. J Invest Dermatol 2004; 123(2): A64

    Google Scholar 

  68. Raptiva® (efalizumab) prescribing information. San Francisco (CA): Genentech, Inc., 2005 Jun

  69. Gottlieb AB, Gordon KB, Lebwohl MG, et al. Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis. J Drugs Dermatol 2004; 3(2): 512–24

    Google Scholar 

  70. Papp K, Menter A, Leonardi C, et al. Efficacy outcomes during extended and long-term use of efalizumab in patients with moderate to severe chronic plaque psoriasis. Poster presented at the 34th annual meeting of the European Society for Dermatological Research; Vienna 2004 Sep 3

  71. Data on file, Serono, 2004

  72. Menter A, Kardatzke D, Rundle AC, Kwon P, Garovoy MR, Leonardi CL. Incidence and prevention of rebound upon efalizumab discontinuation. Poster presented at the 10th International Psoriasis Symposium™ [Poster 34]; 2004 Jun 10-13; Toronto

  73. Leonardi CL, Menter A, Sterry W, Bos JD, Papp KA. Guidelines for the long-term management of plaque psoriasis with continuous efalizumab therapy. Poster presented at the 3rd EADV Spring Symposium; 2005 May 19-22; Sofia

  74. Rosoph L. Safety of efalizumab, a humanized monoclonal antibody, in patients with moderate to severe plaque psoriasis [abstract]. J Eur Acad Derm Venerol 2003; 17: 371

    Article  Google Scholar 

  75. Efalizumab monograph, February 2004. VHA Pharmacy benefits management strategic healthcare group and the medical advisory panel [online]. Available from URL: http://www.vapbm.org/monograph/28578Efalizumab.pdf [Accessed 2005 Apr 8]

  76. Mikuls T, Weaver AL. Lessons learned in the use of tumour necrosis factor-alpha inhibitors in the treatment of rheumatoid arthritis. Curr Rheum Rep 2003; 5: 270–7

    Article  Google Scholar 

  77. US FDA. FDA Arthritis Advisory Committee briefing document. Remicade® (infliximab): efficacy and safety review, 2003 Mar 4 [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/03/briefing/393061_02_A-Abbott-Humira.html [Accessed 2005 Nov 30]

  78. Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27(5): 307–24

    Article  PubMed  CAS  Google Scholar 

  79. Wolfe F, Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004; 50(6): 1740–51

    Article  PubMed  CAS  Google Scholar 

  80. Margolis D, Bilker W, Hennessy S, et al. The risk of malignancy associated with psoriasis. Arch Dermatol 2001; 137: 778–83

    PubMed  CAS  Google Scholar 

  81. Gelfand JM, Berlin J, Voorhees AV, et al. Lymphoma rates are low but increased in patients with psoriasis. Arch Dermatol 2003; 139: 1425–9

    Article  PubMed  Google Scholar 

  82. Jaffery SH, Carrillo M, Betensley AD. Fatal pulmonary non-tuberculous mycobacterial infection in a patient receiving etanercept for rheumatoid arthritis. Chest 2004; 126(4): 944S

    Google Scholar 

  83. Mohan N, Edwards ET, Cupps TR, et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 2001; 44(12): 2862–9

    Article  PubMed  CAS  Google Scholar 

  84. Kwon HJ, Cote TR, Cuffe MS, et al. Case reports of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003 May 20; 138(10): 807–11

    PubMed  Google Scholar 

  85. Anker SD, Coats AJ. How to recover from renaissance? The significance of the results of recover, renaissance, renewal and attach. Int J Cardiol 2002; 86(2-3): 123–30

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

Professor Shear has received no direct payments towards the preparation of this manuscript. He has been a paid consultant, clinical trialist and received educational support from pharmaceutical manufacturers that make and market systemic therapies for psoriasis (including Abbott, Amgen, Biogen, Idec, Centocor, Hoffmann LaRoche, Genentech, Novartis, Schering Canada, Serono, Wyeth and Xoma).

Author information

Authors and Affiliations

  1. Sunnybrook & Women’s College Health Sciences Centre, University of Toronto, 2075 Bayview Avenue, M1-700, Toronto, Ontario, M4N 3M5, Canada

    Neil H. Shear

Authors
  1. Neil H. Shear
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Neil H. Shear.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Shear, N.H. Fulfilling an Unmet Need in Psoriasis. Drug-Safety 29, 49–66 (2006). https://doi.org/10.2165/00002018-200629010-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00002018-200629010-00004

Keywords

Search

Navigation